Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have earned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.30.

IMGN has been the subject of a number of research analyst reports. ValuEngine downgraded ImmunoGen from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 price target on shares of ImmunoGen in a research report on Monday, September 25th. Jefferies Group reiterated a “buy” rating and set a $9.00 price target on shares of ImmunoGen in a research report on Thursday, October 12th. Finally, Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, October 31st.

Shares of ImmunoGen (IMGN) opened at $7.40 on Wednesday. The stock has a market capitalization of $1,150.00, a PE ratio of -5.69 and a beta of 2.20. The company has a current ratio of 2.81, a quick ratio of 2.78 and a debt-to-equity ratio of -0.03. ImmunoGen has a 12-month low of $2.20 and a 12-month high of $8.84.

ImmunoGen (NASDAQ:IMGN) last issued its quarterly earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.42). The firm had revenue of $8.50 million during the quarter, compared to analysts’ expectations of $26.09 million. The company’s revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.51) EPS. sell-side analysts forecast that ImmunoGen will post -0.97 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in IMGN. Arrowstreet Capital Limited Partnership bought a new stake in ImmunoGen in the 2nd quarter worth approximately $102,000. Intl Fcstone Inc. bought a new stake in ImmunoGen in the 2nd quarter worth approximately $115,000. Raymond James Financial Services Advisors Inc. bought a new stake in ImmunoGen in the 2nd quarter worth approximately $126,000. Virginia Retirement Systems ET AL bought a new stake in ImmunoGen in the 3rd quarter worth approximately $136,000. Finally, Cubist Systematic Strategies LLC bought a new stake in ImmunoGen in the 3rd quarter worth approximately $143,000. Institutional investors own 68.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/10/immunogen-inc-imgn-receives-consensus-rating-of-hold-from-brokerages-2.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.